**Upadacitinib Study for Atopic Dermatitis (AD)**: This study is for adults with moderate to severe AD, a skin condition that causes a rash and itching. It examines the safety and effectiveness of the drug **upadacitinib** compared to another drug, **dupilumab**. Participants will receive either upadacitinib or dupilumab and might have their dose adjusted based on their response. The study lasts 32 weeks, with regular hospital or clinic visits for tests and to check for side effects.

Key Points:

• Study Duration: Participants will be involved for about 35 days for screening, then 32 weeks of treatment, and a follow-up of 30 days.
• Regular Visits: Participants must attend regular visits for medical assessments and complete questionnaires.
• Eligibility: Must be 18-64 years old, with a history of inadequate response to dupilumab.

Participants should be aware that the study may have a higher treatment burden compared to their usual care and should consider their ability to commit to the study's duration and visits.